Opaleye Management’s Pasithea Therapeutics KTTA Stock Holding History
Bought
Maintained
Sold
Other funds holding KTTA
Opaleye Management's KTTA Position: Q3 2026 in Review
Opaleye Management sold out of Pasithea Therapeutics (KTTA) in Q3 2026, closing a stake of 2,050,000 shares — an estimated $1.06M sold.
Opaleye Management first reported a position in KTTA in Q2 2026 and held it in 1 quarter. The position peaked at $1.06M in Q2 2026. 26 funds tracked by Wall St. Rank hold KTTA as of Q3 2026.
- Opaleye Management reported no remaining Pasithea Therapeutics position as of Q3 2026 after selling out during the quarter.
- Opaleye Management sold 2,050,000 Pasithea Therapeutics shares in Q3 2026, an estimated $1.06M.
- Opaleye Management first reported a position in Pasithea Therapeutics in Q2 2026 and held it in 1 quarter.
- Opaleye Management's Pasithea Therapeutics position peaked at $1.06M in Q2 2026.
- 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2026.
Based on Opaleye Management's 13F filing for Q3 2026, filed 16 Nov 2026.